statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial

Lyell Immunopharma shares fell following the release of initial clinical data from its Phase 1 trial of LYL797, a reprogrammed CAR T-cell product. The company reported some severe cases reported in...

Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 4.9%

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) rose 4.9% during mid-day trading on Thursday . The company traded as high as $2.17 and last traded at $2.16. Approximately 21,770...

Lyell Immunopharma (NASDAQ:LYEL) Trading 5.9% Higher

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report)'s stock price traded up 5.9% during mid-day trading on Thursday . The stock traded as high as $2.17 and last traded at $2.16. 158,847 shares...

CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)

PRESS RELEASE CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) LONDON 19 March 2024 -- CHARM Therapeutics ( CHARM , The Company ), a 3D deep-learning research company...

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

On track to report initial clinical and translational data from lead CAR T-cell and TIL product candidates in 2024Received Orphan Drug Designation for LYL845 for the treatment of melanomaExpect to...

Commit To Buy Lyell Immunopharma At $2.50, Earn 57.3% Annualized Using Options

Investors eyeing a purchase of Lyell Immunopharma Inc (LYEL) shares, but tentative about paying the going market price of 2.84/share, might benefit from considering selling puts among the...

Lyell Immunopharma Announces Participation in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...

Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 5%

Lyell Immunopharma, Inc. (NASDAQ:LYEL  Get Free Report)s share price was up 5% on Wednesday . The company traded as high as $2.24 and last traded at $2.23. Approximately 861,207 shares...

Ieq Capital LLC Purchases Shares of 82,157 Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Ieq Capital LLC bought a new position in Lyell Immunopharma, Inc. (NASDAQ:LYEL  Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The...

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

Volume	372,722.00
52-Wk High	$3.26
52-Wk Low	$1.18

LYEL Lyell Immunopharma Inc

About

Feed

News

Sentiment

Earnings

Fundamentals